Shannon McCallie, MD
Internal Medicine · Ooltewah, TNNPI 1740275031
Payments from drug & device makers
Across 186 payments — averaging $18.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$765
- AbbVie$370
- Pfizer$326
- GSK$247
- Lilly USA, LLC$166
- Abbott$135
- plus $1K from 29 others
What the payments were for
- Food & beverage$3,36299%
- Education$140%
- Gifts$181%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 41 | $765 |
| AbbVie | 20 | $370 |
| Pfizer | 19 | $326 |
| GSK | 14 | $247 |
| Lilly USA, LLC | 11 | $166 |
| Abbott | 7 | $135 |
| Axsome Therapeutics, Inc. | 3 | $104 |
| Shield Therapeutics Inc | 6 | $103 |
| Astellas Pharma US Inc | 4 | $102 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $91 |
| Boehringer Ingelheim | 5 | $84 |
| AstraZeneca | 5 | $80 |
| Exact Sciences | 4 | $66 |
| Sumitomo Pharma America, Inc. | 3 | $61 |
| Biohaven Pharmaceuticals, Inc. | 4 | $59 |
| Boston Scientific | 3 | $52 |
| Xeris Pharmaceuticals, Inc. | 3 | $50 |
| E.r. Squibb & Sons, L.L.C. | 3 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $44 |
| Novartis | 2 | $42 |
| Amgen | 3 | $42 |
| Medtronic | 2 | $40 |
| Sanofi | 1 | $40 |
| Dexcom, Inc. | 2 | $38 |
| Inspire Medical Systems, Inc. | 2 | $34 |
| Globus Medical | 1 | $30 |
| Gilead | 1 | $29 |
| Sanofi Pasteur Inc. | 2 | $27 |
| Kowa Pharmaceuticals America, Inc. | 1 | $22 |
| Dynavax Technologies Corporation | 1 | $18 |
| Ascend Therapeutics US, LLC | 1 | $18 |
| Lundbeck LLC | 1 | $16 |
| Bayer | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $13 |
How this compares
$3,394 in reported general payments places this provider in the 80th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 110 | $134,444 |
| EliquisApixaban | 82 | $71,893 |
| MounjaroTirzepatide | 37 | $51,203 |
| FarxigaDapagliflozin Propanediol | 45 | $47,483 |
| JardianceEmpagliflozin | 63 | $45,284 |
| TrulicityDulaglutide | 21 | $27,986 |
| XareltoRivaroxaban | 27 | $19,758 |
| MyrbetriqMirabegron | 23 | $16,609 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $15,892 |
| RybelsusSemaglutide | 11 | $9,975 |
| JanuviaSitagliptin Phosphate | 11 | $9,520 |
| Repatha SureclickEvolocumab | 14 | $7,420 |
| Rosuvastatin Calcium | 274 | $4,326 |
| SynthroidLevothyroxine Sodium | 45 | $4,302 |
| Ezetimibe | 85 | $2,922 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $765 | $144,418121 claims |
| Lilly USA, LLCMounjaro, Trulicity | $166 | $79,18958 claims |
| PfizerEliquis | $326 | $71,89382 claims |
| AstraZenecaFarxiga | $80 | $47,48345 claims |
| Boehringer IngelheimJardiance | $84 | $45,28463 claims |
| Johnson & JohnsonXarelto | $13 | $19,75827 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta | $247 | $18,13224 claims |
| Astellas Pharma US IncMyrbetriq | $102 | $16,60923 claims |
| AbbVieSynthroid | $370 | $4,30245 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Ooltewah
- Obadias MarquezOoltewah$2.8M
- Mark McKenzieChattanooga$11.9M
- Bernard GrunstraBristol$6.4M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- Amanda Moore MillerKnoxville$2.3M
- Rick WhilesBristol$1.5M
- John AndersonNashville$1.5M
- David MorinKingsport$1.4M
- John KirbyJefferson City$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.